Alector Inc Market Cap ($252.73 Million)
Market Cap & Net Worth: Alector Inc (ALEC)
Alector Inc market cap. Alector Inc (NASDAQ:ALEC) has a market capitalization of $252.73 Million ($252.73 Million) as of November 7, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15325 globally and #3637 in its home market, demonstrating a 2.23% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alector Inc's stock price $2.29 by its total outstanding shares 110362581 (110.36 Million). Also see Alector Inc (ALEC) cash flow conversion for how efficiently the company converts equity into cash flow.
Alector Inc Market Cap History (2019–2026)
Alector Inc market cap history from 2019 to 2026. Data shows change from $1.90 Billion to $252.73 Million (-23.40% CAGR). Check Alector Inc share price for real-time trading data and today's change.
Index Memberships
Alector Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.59 Trillion | 0.01% | #402 of 976 |
|
NASDAQ Composite
IXIC
|
$39.00 Trillion | 0.00% | #1483 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.01% | #209 of 263 |
Weight: Alector Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Alector Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alector Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Alector Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
8.18x
Alector Inc's market cap is 8.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.90 Billion | $21.22 Million | -$99.81 Million | 89.62x | N/A |
| 2020 | $1.67 Billion | $21.10 Million | -$182.96 Million | 79.14x | N/A |
| 2021 | $2.28 Billion | $207.09 Million | -$28.01 Million | 11.01x | N/A |
| 2022 | $1.02 Billion | $133.62 Million | -$133.31 Million | 7.62x | N/A |
| 2023 | $880.69 Million | $97.06 Million | -$130.39 Million | 9.07x | N/A |
| 2024 | $208.59 Million | $100.56 Million | -$119.05 Million | 2.07x | N/A |
| 2025 | $172.17 Million | $21.05 Million | -$142.93 Million | 8.18x | N/A |
Competitor Companies of ALEC by Market Capitalization
Companies near Alector Inc in the global market cap rankings as of November 7, 2026. Also see Alector Inc (ALEC) total assets for a full breakdown of the balance sheet.
Key companies related to Alector Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Alector Inc (2019–2026)
Market capitalization of Alector Inc from 2019 to today. Between 2019 and today, Alector Inc's market cap moved from $1.90 Billion to $ 252.73 Million, with a yearly change of -23.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $252.73 Million | +46.79% |
| 2025 | $172.17 Million | -17.46% |
| 2024 | $208.59 Million | -76.32% |
| 2023 | $880.69 Million | -13.54% |
| 2022 | $1.02 Billion | -55.30% |
| 2021 | $2.28 Billion | +36.48% |
| 2020 | $1.67 Billion | -12.19% |
| 2019 | $1.90 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Alector Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $252.73 Million USD |
| MoneyControl | $252.73 Million USD |
| MarketWatch | $252.73 Million USD |
| marketcap.company | $252.73 Million USD |
| Reuters | $252.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheim… Read more